Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Dec. 31, 2021 | Feb. 11, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001165320 | |
Entity Registrant Name | GB SCIENCES INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Dec. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 000-55462 | |
Entity Incorporation, State or Country Code | NV | |
Entity Tax Identification Number | 59-3733133 | |
Entity Address, Address Line One | 3550 W. Teco Avenue | |
Entity Address, City or Town | Las Vegas | |
Entity Address, State or Province | NV | |
Entity Address, Postal Zip Code | 89118 | |
City Area Code | 866 | |
Local Phone Number | 721-0297 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 317,435,744 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Dec. 31, 2021 | Mar. 31, 2021 |
Cash and cash equivalents | $ 1,504,330 | $ 793,040 |
Prepaid expenses and other current assets | 112,347 | 256,251 |
Current assets from discontinued operations | 0 | 2,494,564 |
TOTAL CURRENT ASSETS | 1,616,677 | 3,543,855 |
Property and equipment, net | 0 | 25,022 |
Intangible assets, net of accumulated amortization of $87,137 and $43,096 at December 31, 2021 and March 31, 2021, respectively | 2,133,607 | 1,706,762 |
Note receivable | 3,025,000 | 0 |
Long term assets from discontinued operations | 0 | 5,530,415 |
TOTAL ASSETS | 6,775,284 | 10,806,054 |
CURRENT LIABILITIES: | ||
Accounts payable | 1,735,905 | 1,412,459 |
Accrued interest | 370,038 | 493,741 |
Accrued liabilities | 102,774 | 957,946 |
Notes and convertible notes payable and line of credit, net of unamortized discount of $116,704 and $296,504 at December 31, 2021 and March 31, 2021, respectively | 1,508,568 | 3,594,804 |
Indebtedness to related parties | 84,913 | 84,913 |
Income taxes payable from discontinued operations | 836,740 | 761,509 |
Current liabilities from discontinued operations exclusive of income taxes | 0 | 1,293,076 |
TOTAL CURRENT LIABILITIES | 4,638,938 | 8,598,448 |
Convertible notes payable, net of unamortized discount of $113,252 and $154,590 at December 31, 2021 and March 31, 2021, respectively | 333,648 | 292,410 |
Long term liabilities from discontinued operations | 0 | 3,389,124 |
TOTAL LIABILITIES | 4,972,586 | 12,279,982 |
Commitments and contingencies (Note 7) | ||
STOCKHOLDERS' EQUITY/(DEFICIT): | ||
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 317,435,744 and 315,340,411 outstanding at December 31, 2021 and March 31, 2021, respectively | 31,744 | 31,534 |
Additional paid-in capital | 102,682,938 | 102,380,770 |
Accumulated deficit | (100,911,984) | (103,886,232) |
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT) | 1,802,698 | (1,473,928) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 6,775,284 | $ 10,806,054 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) | Dec. 31, 2021 | Mar. 31, 2021 |
Intangible assets, accumulated amortization | $ 87,137 | $ 43,096 |
Unamortized discount, current | 116,704 | 296,504 |
Unamortized discount, noncurrent | $ 113,252 | $ 154,590 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares outstanding (in shares) | 317,435,744 | 315,340,411 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Sales revenue | $ 0 | $ 0 | $ 0 | $ 0 |
Cost of goods sold | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 |
General and administrative expenses | 512,788 | 670,311 | 1,417,738 | 1,677,482 |
LOSS FROM OPERATIONS | (512,788) | (670,311) | (1,417,738) | (1,677,482) |
OTHER INCOME/(EXPENSE) | ||||
Interest expense | (159,478) | (167,120) | (319,976) | (1,249,994) |
Gain on extinguishment | 0 | 467,872 | 0 | 467,872 |
Gain on deconsolidation | 5,206,208 | 0 | 5,206,208 | 0 |
Gain on settlement of accounts payable | 0 | 372,415 | 0 | 372,415 |
Loss on amendment to line of credit | 0 | (650,000) | 0 | (650,000) |
Debt default penalty | 0 | 0 | 0 | (286,059) |
Other income/(expense) | (15,639) | 17,523 | (6,639) | 14,149 |
Total other income/(expense) | 5,031,091 | 40,690 | 4,879,593 | (1,331,617) |
INCOME/(LOSS) BEFORE INCOME TAXES | 4,518,303 | (629,621) | 3,461,855 | (3,009,099) |
Income tax expense | 0 | 0 | 0 | 0 |
INCOME/(LOSS) FROM CONTINUING OPERATIONS | 4,518,303 | (629,621) | 3,461,855 | (3,009,099) |
Income/(loss) from discontinued operations | (192,766) | 35,637 | (324,590) | (237,043) |
Net income (loss) | 4,325,537 | (593,984) | 3,137,265 | (3,246,142) |
Net income/(loss) attributable to common stockholders of GB Sciences, Inc. - basic | ||||
Continuing operations, basic | (4,518,303) | 629,621 | (3,461,855) | 3,009,099 |
Discontinued operations, basic | 192,766 | (35,637) | 324,590 | 237,043 |
Net income (loss) available to common stockholders, basic | 4,325,537 | (593,984) | 3,137,265 | (3,246,142) |
Net income/(loss) attributable to common stockholders of GB Sciences, Inc. - diluted | ||||
Continuing operations, diluted | 4,358,861 | (629,621) | 3,347,016 | (3,009,099) |
Discontinued operations, diluted | (192,766) | 35,637 | (324,590) | (237,043) |
Net income (loss) available to common stockholders, diluted | $ 4,166,095 | $ (593,984) | $ 3,022,426 | $ (3,246,142) |
Net income/(loss) per common share – basic | ||||
Continuing operations, per basic share (in dollars per share) | $ 0.01 | $ 0 | $ 0.01 | $ (0.01) |
Discontinued operations, per basic share (in dollars per share) | 0 | 0 | 0 | 0 |
Net income (loss) available to common stockholders, per basic share (in dollars per share) | 0.01 | 0 | 0.01 | (0.01) |
Net income/(loss) per common share – diluted | ||||
Continuing operations, per diluted share (in dollars per share) | 0.01 | 0 | 0.01 | (0.01) |
Discontinued operations, per diluted share (in dollars per share) | 0 | 0 | 0 | 0 |
Net income (loss) available to common stockholders, per diluted share (in dollars per share) | $ 0.01 | $ 0 | $ 0.01 | $ (0.01) |
Weighted average common shares outstanding - basic (in shares) | 317,435,744 | 280,967,623 | 316,853,591 | 280,119,116 |
Weighted average common shares outstanding - diluted (in shares) | 342,320,490 | 280,967,623 | 343,464,913 | 280,119,116 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 |
OPERATING ACTIVITIES: | ||||||
Net income/(loss) | $ 3,137,265 | $ (3,246,142) | ||||
Loss from discontinued operations | $ (192,766) | $ 35,637 | (324,590) | (237,043) | ||
Net income/(loss) from continuing operations | 3,461,855 | (3,009,099) | ||||
Adjustments to reconcile net income/(loss) to net cash used in operating activities: | ||||||
Depreciation and amortization | 53,424 | 30,097 | ||||
Stock-based compensation and warrant modification expense | 54,167 | 248,850 | ||||
Amortization of debt discount and beneficial conversion feature | 227,537 | 776,908 | ||||
Gain on deconsolidation | $ (5,206,208) | (5,206,208) | 0 | (5,206,208) | 0 | |
Gain on extinguishment | 0 | (467,872) | 0 | (467,872) | ||
Loss on disposal | 15,639 | 0 | ||||
Gain on settlement of accounts payable | 0 | (372,415) | 0 | (372,415) | ||
Loss on amendment to line of credit | 0 | 650,000 | 0 | 650,000 | ||
Debt default penalty | 0 | 286,059 | ||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | 143,904 | (21,449) | ||||
Accounts payable | 899,415 | 20,961 | ||||
Accrued expenses | (855,172) | 319,407 | ||||
Accrued interest | 92,296 | 518,892 | ||||
Indebtedness to related parties | 0 | (254,617) | ||||
Net cash used in operating activities of continuing operations | (1,113,143) | (1,274,278) | ||||
Net cash provided by/(used in) operating activities of discontinued operations | (87,772) | 21,098 | ||||
Net cash used in operating activities | (1,200,915) | (1,253,180) | ||||
INVESTING ACTIVITIES: | ||||||
Proceeds from sale of Nevada subsidiaries | 1,648,772 | 0 | ||||
Acquisition of intangible assets | (100,000) | (326,000) | ||||
Proceeds from note receivable | 0 | 5,051,923 | ||||
Net cash provided by investing activities of continuing operations | 1,548,772 | 4,725,923 | ||||
Net cash provided by/(used in) investing activities of discontinued operations | 1,567 | (131,302) | ||||
Net cash provided by investing activities | 1,550,339 | 4,594,621 | ||||
FINANCING ACTIVITIES: | ||||||
Gross proceeds from warrant exercises | 62,660 | 249,807 | ||||
Proceeds from convertible notes payable | 50,000 | 300,000 | ||||
Proceeds from line of credit | 0 | 375,000 | ||||
Principal payment on notes and convertible notes payable | 0 | (3,156,014) | ||||
Principal payment on note payable to related party | 0 | (151,923) | ||||
Fees for issuance of notes and convertible notes payable | 0 | (34,500) | ||||
Brokerage fees for issuance of common stock and warrants | 0 | (24,983) | ||||
Net cash provided by/(used in) financing activities of continuing operations | 112,660 | (2,442,613) | ||||
Net cash used in financing activities of discontinued operations | (103,387) | (129,237) | ||||
Net cash provided by/(used in) financing activities | 9,273 | (2,571,850) | ||||
Net change in cash and cash equivalents | 358,697 | 769,591 | ||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 1,145,633 | 151,766 | $ 151,766 | |||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 1,504,330 | 1,504,330 | 921,357 | 1,504,330 | 921,357 | $ 1,145,633 |
Less: cash and cash equivalents classified as discontinued operations | 0 | 0 | (150,293) | 0 | (150,293) | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS | $ 1,504,330 | $ 1,504,330 | 771,064 | 1,504,330 | 771,064 | |
Cash paid for interest | 0 | 241,014 | ||||
Cash paid for income tax | 0 | 0 | ||||
Note receivable from sale of Nevada subsidiaries | 3,025,000 | 0 | ||||
Extinguishment of debt and accrued interest owed to the purchasers of Nevada subsidiaries and purchasers' affiliates | 2,612,854 | 0 | ||||
Extinguishment of accrued management fees payable to purchaser of Nevada subsidiaries | 850,000 | 0 | ||||
Depreciation capitalized in inventory (discontinued operations) | 349,015 | 417,616 | ||||
Patent drafting and filing costs capitalized in intangible assets | 342,086 | 45,100 | ||||
Accrued liabilities forgiven in connection with Wellcana letter agreement | 0 | 172,500 | ||||
Brokerage fees for convertible notes | 6,500 | 0 | ||||
Brokerage fees for warrant exercises | 6,266 | 0 | ||||
Stock options issued as compensation for drafting and filing patent applications | $ 63,000 | 28,800 | 168,000 | |||
Induced dividend from warrant exercises | 163,017 | 17,263 | ||||
Accrued interest capitalized in convertible note principal | 0 | 223,094 | ||||
Convertible Notes Payable [Member] | ||||||
FINANCING ACTIVITIES: | ||||||
Beneficial conversion feature on notes payable | $ 0 | $ 196,886 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity/(Deficit) (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Mar. 31, 2020 | 275,541,602 | |||
Balance at Mar. 31, 2020 | $ 27,554 | $ 97,271,157 | $ (97,387,205) | $ (88,494) |
Adjustment to prior period warrant exercise (in shares) | 8,277,851 | |||
Adjustment to prior period warrant exercise | $ 828 | 223,996 | 224,824 | |
Share based compensation expense | 191,500 | 191,500 | ||
Net income (loss) | (3,246,142) | (3,246,142) | ||
Modification of employee options and warrants | 57,350 | 57,350 | ||
Beneficial conversion feature on notes payable | 196,886 | 196,886 | ||
Stock options issued as compensation for services | 168,000 | |||
Stock options issued as compensation for services | 168,000 | 168,000 | ||
Induced Dividend from Warrant Exercises | 17,263 | (17,263) | ||
Beneficial conversion feature on notes payable | 196,886 | 196,886 | ||
Balance (in shares) at Dec. 31, 2020 | 283,819,453 | |||
Balance at Dec. 31, 2020 | $ 28,382 | 98,126,152 | (100,650,610) | (2,496,076) |
Balance (in shares) at Sep. 30, 2020 | 280,532,686 | |||
Balance at Sep. 30, 2020 | $ 28,054 | 97,679,001 | (100,056,626) | (2,349,571) |
Adjustment to prior period warrant exercise (in shares) | 3,286,767 | |||
Adjustment to prior period warrant exercise | $ 328 | 88,415 | 88,743 | |
Share based compensation expense | 191,500 | 191,500 | ||
Net income (loss) | (593,984) | (593,984) | ||
Modification of employee options and warrants | 57,350 | 57,350 | ||
Beneficial conversion feature on notes payable | 46,886 | 46,886 | ||
Stock options issued as compensation for services | 63,000 | 63,000 | ||
Beneficial conversion feature on notes payable | 46,886 | 46,886 | ||
Balance (in shares) at Dec. 31, 2020 | 283,819,453 | |||
Balance at Dec. 31, 2020 | $ 28,382 | 98,126,152 | (100,650,610) | (2,496,076) |
Balance (in shares) at Mar. 31, 2021 | 315,340,411 | |||
Balance at Mar. 31, 2021 | $ 31,534 | 102,380,770 | (103,886,232) | (1,473,928) |
Adjustment to prior period warrant exercise (in shares) | 2,095,333 | |||
Adjustment to prior period warrant exercise | $ 210 | 56,184 | 56,394 | |
Share based compensation expense | 54,167 | |||
Net income (loss) | 3,137,265 | 3,137,265 | ||
Stock options issued as compensation for services | 28,800 | |||
Stock options issued as compensation for services | 28,800 | 28,800 | ||
Induced Dividend from Warrant Exercises | 163,017 | (163,017) | ||
Balance (in shares) at Dec. 31, 2021 | 317,435,744 | |||
Balance at Dec. 31, 2021 | $ 31,744 | 102,682,938 | (100,911,984) | 1,802,698 |
Balance (in shares) at Sep. 30, 2021 | 317,429,078 | |||
Balance at Sep. 30, 2021 | $ 31,743 | 102,667,772 | (105,237,521) | (2,538,006) |
Adjustment to prior period warrant exercise (in shares) | 6,666 | |||
Adjustment to prior period warrant exercise | $ 1 | (1) | ||
Share based compensation expense | 15,167 | 15,167 | ||
Net income (loss) | 4,325,537 | 4,325,537 | ||
Balance (in shares) at Dec. 31, 2021 | 317,435,744 | |||
Balance at Dec. 31, 2021 | $ 31,744 | $ 102,682,938 | $ (100,911,984) | $ 1,802,698 |
Note 1 - Background and Signifi
Note 1 - Background and Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a plant-based research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, minimum essential mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, minimum essential mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary plant-inspired formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and five first GBSGB’s intellectual property portfolio includes five fourteen seven ed 41 October 2021, Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2022. March 31, 2021 not 10 March 31, 2021 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income tax expense and income tax payable have been separated from the comparative period amounts to conform to the current period presentation as income taxes payable from discontinued operations, as the result of the sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 3. Long-Lived Assets We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not December 31, 2021 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first March 31, 2021, December 31, 2021 9 Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 9 606, may may one 606 not Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries has is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Earnings and loss per Share The Company’s basic earnings and loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 131,059,194 and 131,866,787 potentially dilutive common shares at December 31, 2021 December 31, 2020 December 31, 2020 not three nine December 31, 2020, December 31, 2021, not three nine December 31, 2021, three nine December 31, 2021 For the Three Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 4,518,303 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (159,442 ) Effect of assumed conversions (159,442 ) Income from continuing operations plus assumed conversions 4,358,861 Net loss from discontinued operations available to common stockholders (192,766 ) Net income available to common stockholders $ 4,166,095 Weighted-average common shares outstanding 317,435,744 Plus: incremental shares from assumed conversions Warrants 6,174,746 Convertible notes payable 18,710,000 Dilutive potential common shares 24,884,746 Adjusted weighted-average shares 342,320,490 Diluted EPS Net income from continuing operations $ 4,358,861 342,320,490 $ 0.01 Net loss from discontinued operations $ (192,766 ) 342,320,490 $ (0.00 ) Net income $ 4,166,095 342,320,490 $ 0.01 Earnings and loss per Share (continued) For the Nine Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 3,461,855 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (114,839 ) Effect of assumed conversions (114,839 ) Income from continuing operations plus assumed conversions 3,347,016 Net loss from discontinued operations available to common stockholders (324,590 ) Net income available to common stockholders $ 3,022,426 Weighted-average common shares outstanding 316,853,591 Plus: incremental shares from assumed conversions Warrants 7,695,439 Options 205,882 Convertible notes payable 18,710,000 Dilutive potential common shares 26,611,322 Adjusted weighted-average shares 343,464,913 Diluted EPS Net income from continuing operations $ 3,347,016 343,464,913 $ 0.01 Net loss from discontinued operations $ (324,590 ) 343,464,913 $ (0.00 ) Net income $ 3,022,426 343,464,913 $ 0.01 Recent Accounting Pronouncements Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 2 - Going Concern
Note 2 - Going Concern | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $100,911,984 at December 31, 2021 December 31, 2021 March 31, 2021 nine December 31, 2021 nine December 31, 2020 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, it is possible that the COVID- 19 may not 19 In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may |
Note 3 - Discontinued Operation
Note 3 - Discontinued Operations | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Note 3 Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC (the "Nevada Subsidiaries") in discontinued operations due to the sale of the Company's Nevada cultivation and extraction facilities. The assets and liabilities of the Nevada Subsidiaries were deconsolidated at December 31, 2021 9 The assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets as of December 31, 2021 March 31, 2021 December 31, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 1,504,330 $ - $ 1,504,330 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 112,347 - 112,347 256,251 52,492 308,743 TOTAL CURRENT ASSETS 1,616,677 - 1,616,677 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,133,607 - 2,133,607 1,706,762 571,264 2,278,026 Note receivable 3,025,000 - 3,025,000 - - - Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 6,775,284 $ - $ 6,775,284 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,735,905 $ - $ 1,735,905 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 370,038 - 370,038 493,741 49,211 542,952 Accrued expenses 102,774 - 102,774 957,946 105,421 1,063,367 Notes payable, net 1,508,568 - 1,508,568 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income taxes payable - 836,740 836,740 - 761,509 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,802,198 836,740 4,638,938 6,543,863 2,054,585 8,598,448 Convertible notes payable 333,648 - 333,648 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,135,846 $ 836,740 $ 4,972,586 $ 6,836,273 $ 5,443,709 $ 12,279,982 Discontinued Operations - Revenues and Expenses The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three nine December 31, 2021 2020 For the Three Months Ended December 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 811,231 $ 811,231 $ - $ 1,015,464 $ 1,015,464 Cost of goods sold - (832,668 ) (832,668 ) - (596,362 ) (596,362 ) Gross profit/(loss) - (21,437 ) (21,437 ) - 419,102 419,102 General and administrative expenses 512,788 71,648 584,436 670,311 77,064 747,375 INCOME/(LOSS) FROM OPERATIONS (512,788 ) (93,085 ) (605,873 ) (670,311 ) 342,038 (328,273 ) OTHER INCOME/(EXPENSE) Interest expense (159,478 ) (99,681 ) (259,159 ) (167,120 ) (113,241 ) (280,361 ) Gain on extinguishment - - - 467,872 - 467,872 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Gain on settlement of accounts payable - - - 372,415 15,972 388,387 Loss on amendment to line of credit - - - (650,000 ) - (650,000 ) Other income/(expense) (15,639 ) - (15,639 ) 17,523 (2,442 ) 15,081 Total other income/(expense) 5,031,091 (99,681 ) 4,931,410 40,690 (99,711 ) (59,021 ) INCOME/(LOSS) BEFORE INCOME TAXES 4,518,303 (192,766 ) 4,325,537 (629,621 ) 242,327 (387,294 ) Income tax expense - - - - (206,690 ) (206,690 ) NET INCOME/(LOSS) $ 4,518,303 $ (192,766 ) $ 4,325,537 $ (629,621 ) $ 35,637 $ (593,984 ) For the Nine Months Ended December 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 2,830,932 $ 2,830,932 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (1,947,225 ) (1,947,225 ) Gross profit - 297,190 297,190 - 883,707 883,707 General and administrative expenses 1,417,738 264,515 1,682,253 1,677,482 447,885 2,125,367 INCOME/(LOSS) FROM OPERATIONS (1,417,738 ) 32,675 (1,385,063 ) (1,677,482 ) 435,822 (1,241,660 ) OTHER INCOME/(EXPENSE) Interest expense (319,976 ) (302,924 ) (622,900 ) (1,249,994 ) (374,383 ) (1,624,377 ) Gain on extinguishment - - - 467,872 - 467,872 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Gain on settlement of accounts payable - - - 372,415 15,972 388,387 Loss on amendment to line of credit - - - (650,000 ) - (650,000 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) (6,639 ) 20,890 14,251 14,149 (79,890 ) (65,741 ) Total other income/(expense) 4,879,593 (282,034 ) 4,597,559 (1,331,617 ) (438,301 ) (1,769,918 ) INCOME/(LOSS) BEFORE INCOME TAXES 3,461,855 (249,359 ) 3,212,496 (3,009,099 ) (2,479 ) (3,011,578 ) Income tax expense - (75,231 ) (75,231 ) - (234,564 ) (234,564 ) NET INCOME/(LOSS) $ 3,461,855 $ (324,590 ) $ 3,137,265 $ (3,009,099 ) $ (237,043 ) $ (3,246,142 ) Discontinued Operations - Inventory Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's March 31, 2021 December 31, 2021 9 March 31, 2021 Raw materials $ 86,076 Work in progress 743,844 Finished goods 866,195 Subtotal 1,696,115 Allowance to reduce inventory to net realizable value (6,811 ) Total inventory, net $ 1,689,304 Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment was a finance lease for the Nevada Subsidiaries, which is classified as discontinued operations in the Company's unaudited condensed consolidated balance sheet at March 31, 2021. December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the balance sheet as of March 31, 2021. During the nine December 31, 2021 December 31, 2021 9 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 9 not December 29, 2020, no November 30, 2020. December 31, 2021 March 31, 2021 |
Note 4 - Notes Payable and Line
Note 4 - Notes Payable and Line of Credit | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 4 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021 ( 9 July 31, 2021. 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 July 24 9 On December 29, 2020, three $325,000 July 24 July 24 one No November 30, 2020. not July 24 March 31, 2021. December 31, 2021 $325,000 March 31, 2021, December 31, 2021 no 9 Summary of Notes and Convertible Notes Payable As of December 31, 2021 As of December 31, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 190,272 $ - $ 190,272 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 6% Convertible notes payable issued December 2020 through July 2021 (Note 5) 375,000 (116,704 ) 258,296 Total short-term notes payable 1,625,272 (116,704 ) 1,508,568 Long-Term Notes Payable 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (29,997 ) 167,003 6% Convertible notes payable due December 31, 2023 (Note 5) 250,000 (83,355 ) 166,645 Total long-term notes payable $ 447,000 $ (113,352 ) $ 333,648 |
Note 5 - Convertible Notes
Note 5 - Convertible Notes | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Convertible Debt [Text Block] | Note 5 March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three During fiscal year 2018, December 31, 2021 All remaining unconverted notes from the March July 2017 March 31, 2021, $197,000 three September 30, 2023. 10% nine December 31, 2021 $197,000 December 31, 2021 Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. The Company is negotiating the terms of an extension with the note holder. The notes do not nine December 31, 2021 no $1,060,000 December 31, 2021 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On December 29, 2020, November 30, 2020. December 31, 2021 Upon close of the Teco sale on December 31, 2021, 9 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% six September 30, 2020. On May 20, 2020, July 14, 2020, On November 20, 2020, December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2021 July 1, 2022, December 2023. nine December 31, 2021 December 31, 2021 At December 31, 2021 nine December 31, 2021 |
Note 6 - Capital Transactions
Note 6 - Capital Transactions | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 6 Sale of Common Stock and Exercise of Warrants On April 1, 2020, $.05 July 18, 2021, September 30, 2021 three nine December 31, 2021 During the nine December 31, 2021 ten six During the nine December 31, 2021 December 31, 2021 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7 On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020 5 On April 22, 2020, September 17, 2020, From time to time, the Company may not |
Note 8 - Related Party Transact
Note 8 - Related Party Transactions | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 8 As of December 31, 2021 |
Note 9 - Sale of Membership Int
Note 9 - Sale of Membership Interests in Nevada Subsidiaries | 9 Months Ended |
Dec. 31, 2021 | |
Nevada Subsidiaries [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 9 On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 4 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), first March 31, 2023, December 31, 2024. As the result of sale of the Nevada Subsidiaries, the Company recorded a gain on deconsolidation of $5,206,208, calculated as follows: December 31, 2021 Cash payments received, including advancements of $ 400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 As the result of the sale, the income, assets, and cash flows of GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements prior to the sale. |
Note 10 - Subsequent Events
Note 10 - Subsequent Events | 9 Months Ended |
Dec. 31, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 10 On January 14, 2022, 2017 5 On January 20, 2022, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2022. March 31, 2021 not 10 March 31, 2021 |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income tax expense and income tax payable have been separated from the comparative period amounts to conform to the current period presentation as income taxes payable from discontinued operations, as the result of the sale of the Company's Nevada operations. The reclassifications had no |
Discontinued Operations, Policy [Policy Text Block] | Discontinued Operations See Note 3. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not December 31, 2021 |
Inventory, Policy [Policy Text Block] | Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first March 31, 2021, December 31, 2021 9 |
Debt, Policy [Policy Text Block] | Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 9 606, may may one 606 not |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries has is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. |
Earnings Per Share, Policy [Policy Text Block] | Earnings and loss per Share The Company’s basic earnings and loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 131,059,194 and 131,866,787 potentially dilutive common shares at December 31, 2021 December 31, 2020 December 31, 2020 not three nine December 31, 2020, December 31, 2021, not three nine December 31, 2021, three nine December 31, 2021 For the Three Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 4,518,303 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (159,442 ) Effect of assumed conversions (159,442 ) Income from continuing operations plus assumed conversions 4,358,861 Net loss from discontinued operations available to common stockholders (192,766 ) Net income available to common stockholders $ 4,166,095 Weighted-average common shares outstanding 317,435,744 Plus: incremental shares from assumed conversions Warrants 6,174,746 Convertible notes payable 18,710,000 Dilutive potential common shares 24,884,746 Adjusted weighted-average shares 342,320,490 Diluted EPS Net income from continuing operations $ 4,358,861 342,320,490 $ 0.01 Net loss from discontinued operations $ (192,766 ) 342,320,490 $ (0.00 ) Net income $ 4,166,095 342,320,490 $ 0.01 Earnings and loss per Share (continued) For the Nine Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 3,461,855 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (114,839 ) Effect of assumed conversions (114,839 ) Income from continuing operations plus assumed conversions 3,347,016 Net loss from discontinued operations available to common stockholders (324,590 ) Net income available to common stockholders $ 3,022,426 Weighted-average common shares outstanding 316,853,591 Plus: incremental shares from assumed conversions Warrants 7,695,439 Options 205,882 Convertible notes payable 18,710,000 Dilutive potential common shares 26,611,322 Adjusted weighted-average shares 343,464,913 Diluted EPS Net income from continuing operations $ 3,347,016 343,464,913 $ 0.01 Net loss from discontinued operations $ (324,590 ) 343,464,913 $ (0.00 ) Net income $ 3,022,426 343,464,913 $ 0.01 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not |
Note 1 - Background and Signi_2
Note 1 - Background and Significant Accounting Policies (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | For the Three Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 4,518,303 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (159,442 ) Effect of assumed conversions (159,442 ) Income from continuing operations plus assumed conversions 4,358,861 Net loss from discontinued operations available to common stockholders (192,766 ) Net income available to common stockholders $ 4,166,095 Weighted-average common shares outstanding 317,435,744 Plus: incremental shares from assumed conversions Warrants 6,174,746 Convertible notes payable 18,710,000 Dilutive potential common shares 24,884,746 Adjusted weighted-average shares 342,320,490 Diluted EPS Net income from continuing operations $ 4,358,861 342,320,490 $ 0.01 Net loss from discontinued operations $ (192,766 ) 342,320,490 $ (0.00 ) Net income $ 4,166,095 342,320,490 $ 0.01 For the Nine Months Ended December 31, 2021 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 3,461,855 Plus: Income impact of assumed conversions Interest expense on convertible notes payable (114,839 ) Effect of assumed conversions (114,839 ) Income from continuing operations plus assumed conversions 3,347,016 Net loss from discontinued operations available to common stockholders (324,590 ) Net income available to common stockholders $ 3,022,426 Weighted-average common shares outstanding 316,853,591 Plus: incremental shares from assumed conversions Warrants 7,695,439 Options 205,882 Convertible notes payable 18,710,000 Dilutive potential common shares 26,611,322 Adjusted weighted-average shares 343,464,913 Diluted EPS Net income from continuing operations $ 3,347,016 343,464,913 $ 0.01 Net loss from discontinued operations $ (324,590 ) 343,464,913 $ (0.00 ) Net income $ 3,022,426 343,464,913 $ 0.01 |
Note 3 - Discontinued Operati_2
Note 3 - Discontinued Operations (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Disposal Groups, Including Discontinued Operations [Table Text Block] | December 31, 2021 March 31, 2021 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 1,504,330 $ - $ 1,504,330 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 112,347 - 112,347 256,251 52,492 308,743 TOTAL CURRENT ASSETS 1,616,677 - 1,616,677 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,133,607 - 2,133,607 1,706,762 571,264 2,278,026 Note receivable 3,025,000 - 3,025,000 - - - Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 6,775,284 $ - $ 6,775,284 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,735,905 $ - $ 1,735,905 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 370,038 - 370,038 493,741 49,211 542,952 Accrued expenses 102,774 - 102,774 957,946 105,421 1,063,367 Notes payable, net 1,508,568 - 1,508,568 3,594,804 485,000 4,079,804 Indebtedness to related parties 84,913 - 84,913 84,913 - 84,913 Income taxes payable - 836,740 836,740 - 761,509 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,802,198 836,740 4,638,938 6,543,863 2,054,585 8,598,448 Convertible notes payable 333,648 - 333,648 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,135,846 $ 836,740 $ 4,972,586 $ 6,836,273 $ 5,443,709 $ 12,279,982 For the Three Months Ended December 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 811,231 $ 811,231 $ - $ 1,015,464 $ 1,015,464 Cost of goods sold - (832,668 ) (832,668 ) - (596,362 ) (596,362 ) Gross profit/(loss) - (21,437 ) (21,437 ) - 419,102 419,102 General and administrative expenses 512,788 71,648 584,436 670,311 77,064 747,375 INCOME/(LOSS) FROM OPERATIONS (512,788 ) (93,085 ) (605,873 ) (670,311 ) 342,038 (328,273 ) OTHER INCOME/(EXPENSE) Interest expense (159,478 ) (99,681 ) (259,159 ) (167,120 ) (113,241 ) (280,361 ) Gain on extinguishment - - - 467,872 - 467,872 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Gain on settlement of accounts payable - - - 372,415 15,972 388,387 Loss on amendment to line of credit - - - (650,000 ) - (650,000 ) Other income/(expense) (15,639 ) - (15,639 ) 17,523 (2,442 ) 15,081 Total other income/(expense) 5,031,091 (99,681 ) 4,931,410 40,690 (99,711 ) (59,021 ) INCOME/(LOSS) BEFORE INCOME TAXES 4,518,303 (192,766 ) 4,325,537 (629,621 ) 242,327 (387,294 ) Income tax expense - - - - (206,690 ) (206,690 ) NET INCOME/(LOSS) $ 4,518,303 $ (192,766 ) $ 4,325,537 $ (629,621 ) $ 35,637 $ (593,984 ) For the Nine Months Ended December 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 2,830,932 $ 2,830,932 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (1,947,225 ) (1,947,225 ) Gross profit - 297,190 297,190 - 883,707 883,707 General and administrative expenses 1,417,738 264,515 1,682,253 1,677,482 447,885 2,125,367 INCOME/(LOSS) FROM OPERATIONS (1,417,738 ) 32,675 (1,385,063 ) (1,677,482 ) 435,822 (1,241,660 ) OTHER INCOME/(EXPENSE) Interest expense (319,976 ) (302,924 ) (622,900 ) (1,249,994 ) (374,383 ) (1,624,377 ) Gain on extinguishment - - - 467,872 - 467,872 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Gain on settlement of accounts payable - - - 372,415 15,972 388,387 Loss on amendment to line of credit - - - (650,000 ) - (650,000 ) Debt default penalty - - - (286,059 ) - (286,059 ) Other income/(expense) (6,639 ) 20,890 14,251 14,149 (79,890 ) (65,741 ) Total other income/(expense) 4,879,593 (282,034 ) 4,597,559 (1,331,617 ) (438,301 ) (1,769,918 ) INCOME/(LOSS) BEFORE INCOME TAXES 3,461,855 (249,359 ) 3,212,496 (3,009,099 ) (2,479 ) (3,011,578 ) Income tax expense - (75,231 ) (75,231 ) - (234,564 ) (234,564 ) NET INCOME/(LOSS) $ 3,461,855 $ (324,590 ) $ 3,137,265 $ (3,009,099 ) $ (237,043 ) $ (3,246,142 ) |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, 2021 Raw materials $ 86,076 Work in progress 743,844 Finished goods 866,195 Subtotal 1,696,115 Allowance to reduce inventory to net realizable value (6,811 ) Total inventory, net $ 1,689,304 |
Note 4 - Notes Payable and Li_2
Note 4 - Notes Payable and Line of Credit (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | As of December 31, 2021 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 4) $ 190,272 $ - $ 190,272 6% Convertible promissory notes payable (Note 5) 1,060,000 - 1,060,000 6% Convertible notes payable issued December 2020 through July 2021 (Note 5) 375,000 (116,704 ) 258,296 Total short-term notes payable 1,625,272 (116,704 ) 1,508,568 Long-Term Notes Payable 6% Convertible promissory notes payable due September 30, 2023 (Note 5) 197,000 (29,997 ) 167,003 6% Convertible notes payable due December 31, 2023 (Note 5) 250,000 (83,355 ) 166,645 Total long-term notes payable $ 447,000 $ (113,352 ) $ 333,648 |
Note 9 - Sale of Membership I_2
Note 9 - Sale of Membership Interests in Nevada Subsidiaries (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Notes Tables | |
Schedule of Deconsolidation [Table Text Block] | December 31, 2021 Cash payments received, including advancements of $ 400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 |
Note 1 - Background and Signi_3
Note 1 - Background and Significant Accounting Policies (Details Textual) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021USD ($)shares | Dec. 31, 2020shares | Dec. 31, 2021USD ($)shares | Dec. 31, 2020shares | |
Impairment, Long-Lived Asset, Held-for-Use, Total | $ 0 | |||
Inventory, Net, Total | $ 0 | $ 0 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 106,174,448 | 131,059,194 | 104,447,872 | 131,866,787 |
Number of Operating Segments | 1 |
Note 1 - Background and Signi_4
Note 1 - Background and Significant Accounting Policies - Computation of Diluted Earnings Per Share (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Net income from continuing operations available to common stockholders | $ 4,518,303 | $ (629,621) | $ 3,461,855 | $ (3,009,099) |
Interest expense on convertible notes payable | 159,442 | 114,839 | ||
Effect of assumed conversions | (159,442) | (114,839) | ||
Continuing operations, diluted | 4,358,861 | (629,621) | 3,347,016 | (3,009,099) |
Discontinued operations, diluted | (192,766) | 35,637 | (324,590) | (237,043) |
Net income (loss) available to common stockholders, diluted | $ 4,166,095 | $ (593,984) | $ 3,022,426 | $ (3,246,142) |
Weighted-average common shares outstanding (in shares) | 317,435,744 | 280,967,623 | 316,853,591 | 280,119,116 |
Warrants (in shares) | 6,174,746 | |||
Convertible notes payable (in shares) | 18,710,000 | 18,710,000 | ||
Dilutive potential common shares (in shares) | 24,884,746 | 26,611,322 | ||
Adjusted weighted-average shares (in shares) | 342,320,490 | 280,967,623 | 343,464,913 | 280,119,116 |
Continuing operations, per diluted share (in dollars per share) | $ 0.01 | $ 0 | $ 0.01 | $ (0.01) |
Discontinued operations, per diluted share (in dollars per share) | 0 | 0 | 0 | 0 |
Net income (loss) available to common stockholders, per diluted share (in dollars per share) | $ 0.01 | $ 0 | $ 0.01 | $ (0.01) |
Warrant [Member] | ||||
Warrants (in shares) | 7,695,439 | |||
Share-based Payment Arrangement, Option [Member] | ||||
Warrants (in shares) | 205,882 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (100,911,984) | $ (103,886,232) | |
Working Capital (Deficit) | (3,022,261) | (5,054,593) | |
Accrued Income Taxes, Current | 836,740 | 761,509 | |
Net Cash Provided by (Used in) Operating Activities, Total | (1,200,915) | $ (1,253,180) | |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | (87,772) | 21,098 | |
Discontinued Operations [Member] | |||
Working Capital (Deficit) | 1,201,488 | ||
Accrued Income Taxes, Current | 836,740 | $ 761,509 | |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | $ (87,772) | $ 21,098 |
Note 3 - Discontinued Operati_3
Note 3 - Discontinued Operations (Details Textual) - USD ($) | 9 Months Ended | 25 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Mar. 31, 2021 | Nov. 27, 2019 | |
Inventory, Net, Total | $ 0 | $ 0 | |||
Proceeds from Lines of Credit, Total | 0 | $ 375,000 | |||
Line of Credit [Member] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | ||||
Proceeds from Lines of Credit, Total | 485,000 | ||||
Line of Credit Facility, Maximum Borrowing Capacity, Increased | 15,000 | ||||
Long-term Line of Credit, Total | 485,000 | 485,000 | |||
Interest Payable | 49,211 | 49,211 | |||
Discontinued Operations [Member] | |||||
Inventory, Net, Total | 0 | $ 0 | $ 1,689,304 | ||
Finance Lease Costs | 417,820 | ||||
Finance Lease, Interest Expense | 301,796 | ||||
Finance Lease, Right-of-Use Asset, Amortization | $ 116,024 | ||||
Maximum [Member] | |||||
Lessee, Finance Lease, Discount Rate | 11.50% | 11.50% |
Note 3 - Discontinued Operati_4
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 |
Cash | $ 1,504,330 | $ 1,504,330 | $ 1,504,330 | $ 793,040 | ||
Inventory, net | 0 | 0 | 0 | |||
Prepaid and other current assets | 112,347 | 112,347 | 112,347 | 256,251 | ||
TOTAL CURRENT ASSETS | 1,616,677 | 1,616,677 | 1,616,677 | 3,543,855 | ||
Property and equipment, net | 0 | 0 | 0 | 25,022 | ||
Intangible assets, net | 2,133,607 | 2,133,607 | 2,133,607 | 1,706,762 | ||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 3,025,000 | 3,025,000 | 0 | ||
TOTAL ASSETS | 6,775,284 | 6,775,284 | 6,775,284 | 10,806,054 | ||
Accounts payable | 1,735,905 | 1,735,905 | 1,735,905 | 1,412,459 | ||
Accrued interest | 370,038 | 370,038 | 370,038 | 493,741 | ||
Accrued expenses | 102,774 | 102,774 | 102,774 | 957,946 | ||
Indebtedness to related parties | 84,913 | 84,913 | 84,913 | 84,913 | ||
Income taxes payable | 836,740 | 836,740 | 836,740 | 761,509 | ||
TOTAL CURRENT LIABILITIES | 4,638,938 | 4,638,938 | 4,638,938 | 8,598,448 | ||
Convertible notes payable | 333,648 | 333,648 | 333,648 | 292,410 | ||
TOTAL LIABILITIES | 4,972,586 | 4,972,586 | 4,972,586 | 12,279,982 | ||
Sales revenue | 0 | $ 0 | 0 | $ 0 | ||
Cost of goods sold | 0 | 0 | 0 | 0 | ||
Gross profit | 0 | 0 | 0 | 0 | ||
General and administrative expenses | 512,788 | 670,311 | 1,417,738 | 1,677,482 | ||
Interest expense | (159,478) | (167,120) | (319,976) | (1,249,994) | ||
Gain on extinguishment | 0 | 467,872 | 0 | 467,872 | ||
Gain on deconsolidation | 5,206,208 | 5,206,208 | 0 | 5,206,208 | 0 | |
Gain on settlement of accounts payable | 0 | 372,415 | 0 | 372,415 | ||
Loss on amendment to line of credit | 0 | (650,000) | 0 | (650,000) | ||
Other income/(expense) | (15,639) | 17,523 | (6,639) | 14,149 | ||
Total other income/(expense) | 5,031,091 | 40,690 | 4,879,593 | (1,331,617) | ||
Income tax expense | 0 | 0 | 0 | 0 | ||
NET INCOME/(LOSS) | (192,766) | 35,637 | (324,590) | (237,043) | ||
Debt default penalty | 0 | 0 | 0 | (286,059) | ||
INCOME/(LOSS) BEFORE INCOME TAXES | 4,518,303 | (629,621) | 3,461,855 | (3,009,099) | ||
NET INCOME/(LOSS) | 3,137,265 | (3,246,142) | ||||
Continuing Operations [Member] | ||||||
Cash | 1,504,330 | 1,504,330 | 1,504,330 | 793,040 | ||
Accounts receivable, net | 0 | 0 | 0 | 0 | ||
Inventory, net | 0 | 0 | 0 | 0 | ||
Prepaid and other current assets | 112,347 | 112,347 | 112,347 | 256,251 | ||
TOTAL CURRENT ASSETS | 1,616,677 | 1,616,677 | 1,616,677 | 1,049,291 | ||
Property and equipment, net | 0 | 0 | 0 | 25,022 | ||
Intangible assets, net | 2,133,607 | 2,133,607 | 2,133,607 | 1,706,762 | ||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 3,025,000 | 3,025,000 | 0 | ||
Deposits and other noncurrent assets | 0 | 0 | 0 | 0 | ||
TOTAL ASSETS | 6,775,284 | 6,775,284 | 6,775,284 | 2,781,075 | ||
Accounts payable | 1,735,905 | 1,735,905 | 1,735,905 | 1,412,459 | ||
Accrued interest | 370,038 | 370,038 | 370,038 | 493,741 | ||
Accrued expenses | 102,774 | 102,774 | 102,774 | 957,946 | ||
Notes payable, net | 1,508,568 | 1,508,568 | 1,508,568 | 3,594,804 | ||
Indebtedness to related parties | 84,913 | 84,913 | 84,913 | 84,913 | ||
Income taxes payable | 0 | 0 | 0 | 0 | ||
Finance lease obligations, current | 0 | 0 | 0 | 0 | ||
TOTAL CURRENT LIABILITIES | 3,802,198 | 3,802,198 | 3,802,198 | 6,543,863 | ||
Convertible notes payable | 333,648 | 333,648 | 333,648 | 292,410 | ||
Finance lease obligations, long term | 0 | 0 | 0 | 0 | ||
TOTAL LIABILITIES | 4,135,846 | 4,135,846 | 4,135,846 | 6,836,273 | ||
Sales revenue | 0 | 0 | 0 | 0 | ||
Cost of goods sold | 0 | 0 | 0 | 0 | ||
Gross profit | 0 | 0 | 0 | 0 | ||
General and administrative expenses | 512,788 | 670,311 | 1,417,738 | 1,677,482 | ||
INCOME/(LOSS) FROM OPERATIONS | (512,788) | (670,311) | (1,417,738) | (1,677,482) | ||
Interest expense | (159,478) | (167,120) | (319,976) | (1,249,994) | ||
Gain on extinguishment | 0 | 467,872 | 0 | 467,872 | ||
Gain on deconsolidation | 5,206,208 | 0 | 5,206,208 | 0 | ||
Gain on settlement of accounts payable | 0 | 372,415 | 0 | 372,415 | ||
Loss on amendment to line of credit | 0 | (650,000) | 0 | (650,000) | ||
Other income/(expense) | (15,639) | 17,523 | (6,639) | 14,149 | ||
Total other income/(expense) | 5,031,091 | 40,690 | 4,879,593 | (1,331,617) | ||
INCOME/(LOSS) BEFORE INCOME TAXES | 4,518,303 | (629,621) | ||||
Income tax expense | 0 | 0 | 0 | 0 | ||
NET INCOME/(LOSS) | 4,518,303 | (629,621) | ||||
Debt default penalty | 0 | (286,059) | ||||
INCOME/(LOSS) BEFORE INCOME TAXES | 3,461,855 | (3,009,099) | ||||
NET INCOME/(LOSS) | 3,461,855 | (3,009,099) | ||||
Discontinued Operations [Member] | ||||||
Cash | 0 | 0 | 0 | 352,593 | ||
Accounts receivable, net | 0 | 0 | 0 | 400,175 | ||
Inventory, net | 0 | 0 | 0 | 1,689,304 | ||
Prepaid and other current assets | 0 | 0 | 0 | 52,492 | ||
TOTAL CURRENT ASSETS | 0 | 0 | 0 | 2,494,564 | ||
Property and equipment, net | 0 | 0 | 0 | 4,876,247 | ||
Intangible assets, net | 0 | 0 | 0 | 571,264 | ||
Financing Receivable, after Allowance for Credit Loss, Total | 0 | 0 | 0 | 0 | ||
Deposits and other noncurrent assets | 0 | 0 | 0 | 82,904 | ||
TOTAL ASSETS | 0 | 0 | 0 | 8,024,979 | ||
Accounts payable | 0 | 0 | 0 | 509,477 | ||
Accrued interest | 0 | 0 | 0 | 49,211 | ||
Accrued expenses | 0 | 0 | 0 | 105,421 | ||
Notes payable, net | 0 | 0 | 0 | 485,000 | ||
Indebtedness to related parties | 0 | 0 | 0 | 0 | ||
Income taxes payable | 836,740 | 836,740 | 836,740 | 761,509 | ||
Finance lease obligations, current | 0 | 0 | 0 | 143,967 | ||
TOTAL CURRENT LIABILITIES | 836,740 | 836,740 | 836,740 | 2,054,585 | ||
Convertible notes payable | 0 | 0 | 0 | 0 | ||
Finance lease obligations, long term | 0 | 0 | 0 | 3,389,124 | ||
TOTAL LIABILITIES | 836,740 | 836,740 | 836,740 | 5,443,709 | ||
Sales revenue | 811,231 | 1,015,464 | 3,369,812 | 2,830,932 | ||
Cost of goods sold | (832,668) | (596,362) | (3,072,622) | (1,947,225) | ||
Gross profit | (21,437) | 419,102 | 297,190 | 883,707 | ||
General and administrative expenses | 71,648 | 77,064 | 264,515 | 447,885 | ||
INCOME/(LOSS) FROM OPERATIONS | (93,085) | 342,038 | 32,675 | 435,822 | ||
Interest expense | (99,681) | (113,241) | (302,924) | (374,383) | ||
Gain on extinguishment | 0 | 0 | 0 | 0 | ||
Gain on deconsolidation | 0 | 0 | 0 | 0 | ||
Gain on settlement of accounts payable | 0 | 15,972 | 0 | 15,972 | ||
Loss on amendment to line of credit | 0 | 0 | 0 | 0 | ||
Other income/(expense) | 0 | (2,442) | 20,890 | (79,890) | ||
Total other income/(expense) | (99,681) | (99,711) | (282,034) | (438,301) | ||
INCOME/(LOSS) BEFORE INCOME TAXES | (192,766) | 242,327 | ||||
Income tax expense | 0 | (206,690) | (75,231) | (234,564) | ||
NET INCOME/(LOSS) | (192,766) | 35,637 | ||||
Debt default penalty | 0 | 0 | ||||
INCOME/(LOSS) BEFORE INCOME TAXES | (249,359) | (2,479) | ||||
NET INCOME/(LOSS) | (324,590) | (237,043) | ||||
Segment, Continuing and Discontinued Operations [Member] | ||||||
Cash | 1,504,330 | 1,504,330 | 1,504,330 | 1,145,633 | ||
Accounts receivable, net | 0 | 0 | 0 | 400,175 | ||
Inventory, net | 0 | 0 | 0 | 1,689,304 | ||
Prepaid and other current assets | 112,347 | 112,347 | 112,347 | 308,743 | ||
TOTAL CURRENT ASSETS | 1,616,677 | 1,616,677 | 1,616,677 | 3,543,855 | ||
Property and equipment, net | 0 | 0 | 0 | 4,901,269 | ||
Intangible assets, net | 2,133,607 | 2,133,607 | 2,133,607 | 2,278,026 | ||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 3,025,000 | 3,025,000 | 0 | ||
Deposits and other noncurrent assets | 0 | 0 | 0 | 82,904 | ||
TOTAL ASSETS | 6,775,284 | 6,775,284 | 6,775,284 | 10,806,054 | ||
Accounts payable | 1,735,905 | 1,735,905 | 1,735,905 | 1,921,936 | ||
Accrued interest | 370,038 | 370,038 | 370,038 | 542,952 | ||
Accrued expenses | 102,774 | 102,774 | 102,774 | 1,063,367 | ||
Notes payable, net | 1,508,568 | 1,508,568 | 1,508,568 | 4,079,804 | ||
Indebtedness to related parties | 84,913 | 84,913 | 84,913 | 84,913 | ||
Income taxes payable | 836,740 | 836,740 | 836,740 | 761,509 | ||
Finance lease obligations, current | 0 | 0 | 0 | 143,967 | ||
TOTAL CURRENT LIABILITIES | 4,638,938 | 4,638,938 | 4,638,938 | 8,598,448 | ||
Convertible notes payable | 333,648 | 333,648 | 333,648 | 292,410 | ||
Finance lease obligations, long term | 0 | 0 | 0 | 3,389,124 | ||
TOTAL LIABILITIES | $ 4,972,586 | 4,972,586 | 4,972,586 | $ 12,279,982 | ||
Sales revenue | 811,231 | 1,015,464 | 3,369,812 | 2,830,932 | ||
Cost of goods sold | (832,668) | (596,362) | (3,072,622) | (1,947,225) | ||
Gross profit | (21,437) | 419,102 | 297,190 | 883,707 | ||
General and administrative expenses | 584,436 | 747,375 | 1,682,253 | 2,125,367 | ||
INCOME/(LOSS) FROM OPERATIONS | (605,873) | (328,273) | (1,385,063) | (1,241,660) | ||
Interest expense | (259,159) | (280,361) | (622,900) | (1,624,377) | ||
Gain on extinguishment | 0 | 467,872 | 0 | 467,872 | ||
Gain on deconsolidation | 5,206,208 | 0 | 5,206,208 | 0 | ||
Gain on settlement of accounts payable | 0 | 388,387 | 0 | 388,387 | ||
Loss on amendment to line of credit | 0 | (650,000) | 0 | (650,000) | ||
Other income/(expense) | (15,639) | 15,081 | 14,251 | (65,741) | ||
Total other income/(expense) | 4,931,410 | (59,021) | 4,597,559 | (1,769,918) | ||
INCOME/(LOSS) BEFORE INCOME TAXES | 4,325,537 | (387,294) | ||||
Income tax expense | 0 | (206,690) | (75,231) | (234,564) | ||
NET INCOME/(LOSS) | $ 4,325,537 | $ (593,984) | ||||
Debt default penalty | 0 | (286,059) | ||||
INCOME/(LOSS) BEFORE INCOME TAXES | 3,212,496 | (3,011,578) | ||||
NET INCOME/(LOSS) | $ 3,137,265 | $ (3,246,142) |
Note 3 - Discontinued Operati_5
Note 3 - Discontinued Operations - Schedule of Inventory (Details) | Dec. 31, 2021USD ($) |
Total inventory, net | $ 0 |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |
Raw materials | 86,076 |
Work in progress | 743,844 |
Finished goods | 866,195 |
Subtotal | 1,696,115 |
Allowance to reduce inventory to net realizable value | (6,811) |
Total inventory, net | $ 1,689,304 |
Note 4 - Notes Payable and Li_3
Note 4 - Notes Payable and Line of Credit (Details Textual) - USD ($) | Dec. 31, 2021 | Dec. 14, 2021 | Dec. 29, 2020 | Oct. 23, 2017 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | Aug. 10, 2020 | Jul. 24, 2020 |
Financing Receivable, after Allowance for Credit Loss, Total | $ 3,025,000 | $ 3,025,000 | $ 3,025,000 | $ 3,025,000 | $ 0 | |||||||
Gain (Loss) on Amendment to Line of Credit | 0 | $ (650,000) | 0 | $ (650,000) | ||||||||
GB Sciences Nopah, LLC [Member] | ||||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 8.00% | |||||||||||
Extinguishment of Debt, Amount | $ 3,588,540 | |||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 3,025,000 | 3,025,000 | 3,025,000 | 3,025,000 | ||||||||
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member] | ||||||||||||
Extinguishment of Debt, Amount | 74,647 | $ 74,647 | ||||||||||
Teco Subsidiaries [Member] | The July 24 Note [Member] | ||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | 1,025,000 | $ 3,025,000 | 1,025,000 | 1,025,000 | 1,025,000 | |||||||
Increase (Decrease) in Notes Receivable, Current | 975,000 | |||||||||||
Notes Receivable, Maximum Allowed Prepayments On Note | 325,000 | |||||||||||
Disposal Group, Including Discontinued Operation, Consideration | $ 4,000,000 | |||||||||||
Gain (Loss) on Amendment to Line of Credit | $ (650,000) | |||||||||||
Notes Receivable, Additional Advances | 50,000 | |||||||||||
Interest and Debt Expense, Total | 12,510 | |||||||||||
The July 24 Note [Member] | Revolving Credit Facility [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 500,000 | |||||||||||
The July 24 Note [Member] | Teco Subsidiaries [Member] | ||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | |||||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | |||||||||||
Promissory Note [Member] | ||||||||||||
Debt Instrument, Face Amount | 447,000 | 447,000 | 447,000 | 447,000 | ||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | ||||||||||
Debt Instrument, Face Amount | $ 700,000 | |||||||||||
Debt Instrument, Term (Year) | 3 years | |||||||||||
Debt Instrument, Present Value | $ 521,067 | |||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | |||||||||||
Debt Instrument, Unamortized Discount, Total | $ 178,933 | |||||||||||
Notes Payable, Current, Total | $ 369,445 | $ 369,445 | $ 369,445 | $ 369,445 | ||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member] | ||||||||||||
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition | $ 190,272 | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | ||||||||||||
Payments to Acquire License | $ 500,000 | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member] | ||||||||||||
Ownership of Licence | 100.00% | |||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member] | ||||||||||||
Ownership of Licence | 100.00% |
Note 4 - Notes Payable and Li_4
Note 4 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($) | Dec. 31, 2021 | Mar. 31, 2021 | Oct. 23, 2017 |
Discount, short-term notes payable | $ (116,704) | $ (296,504) | |
Discount, long-term notes payable | (113,252) | $ (154,590) | |
Promissory Note [Member] | |||
Face value, short-term notes payable | 447,000 | ||
Discount, long-term notes payable | (113,352) | ||
Carrying value, long-term notes payable | 333,648 | ||
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | |||
Face value, short-term notes payable | $ 700,000 | ||
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member] | |||
Face value, short-term notes payable | 197,000 | ||
Discount, long-term notes payable | (29,997) | ||
Carrying value, long-term notes payable | 167,003 | ||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | |||
Discount, short-term notes payable | (116,704) | ||
Discount, long-term notes payable | (83,355) | ||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member] | |||
Face value, short-term notes payable | 250,000 | ||
Discount, long-term notes payable | (83,355) | ||
Carrying value, long-term notes payable | 166,645 | ||
Note Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||
Face value, short-term notes payable | 190,272 | ||
Discount, short-term notes payable | 0 | ||
Carrying value, short-term notes payable | 190,272 | ||
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member] | |||
Face value, short-term notes payable | 1,060,000 | ||
Discount, short-term notes payable | 0 | ||
Carrying value, short-term notes payable | 1,060,000 | ||
Convertible Notes Payable [Member] | The 6 % Convertible Note Offering Dated December 2020 [Member] | |||
Face value, short-term notes payable | 375,000 | ||
Discount, short-term notes payable | (116,704) | ||
Carrying value, short-term notes payable | 258,296 | ||
Promissory Note [Member] | |||
Face value, short-term notes payable | 1,625,272 | ||
Discount, short-term notes payable | (116,704) | ||
Carrying value, short-term notes payable | $ 1,508,568 |
Note 5 - Convertible Notes (Det
Note 5 - Convertible Notes (Details Textual) | Dec. 16, 2020USD ($) | Jul. 14, 2020USD ($) | Apr. 22, 2020USD ($) | Nov. 18, 2019USD ($)$ / sharesshares | Oct. 30, 2019USD ($)$ / sharesshares | Apr. 23, 2019USD ($)$ / shares | Feb. 28, 2019USD ($)$ / shares | Jul. 31, 2017USD ($)$ / shares | Mar. 31, 2017USD ($)$ / shares | Dec. 31, 2021USD ($)Rate | Dec. 31, 2020USD ($) | May 31, 2017USD ($)$ / sharesshares | Sep. 30, 2021USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2021USD ($)Rate | Dec. 31, 2020USD ($) | Mar. 31, 2021USD ($)$ / sharesshares | Mar. 31, 2020USD ($) | Mar. 31, 2018USD ($) | Dec. 18, 2020$ / shares | Dec. 09, 2020USD ($) | Nov. 20, 2020USD ($) |
Amortization of Debt Discount (Premium) | $ 227,537 | $ 776,908 | ||||||||||||||||||||
Debt Default Penalty | $ 0 | $ 0 | 0 | 286,059 | ||||||||||||||||||
Proceeds from Convertible Debt | 50,000 | 300,000 | ||||||||||||||||||||
Convertible Notes Payable, Current | 1,508,568 | 1,508,568 | $ 3,594,804 | |||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 116,704 | 116,704 | 296,504 | |||||||||||||||||||
Convertible Notes Payable, Noncurrent | 333,648 | 333,648 | 292,410 | |||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | $ 113,252 | $ 113,252 | $ 154,590 | |||||||||||||||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | ||||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 15.00% | |||||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | |||||||||||||||||||||
Litigation Settlement, Amount Final Settlement | $ 3,006,015 | $ 3,006,015 | ||||||||||||||||||||
Litigation Settlement, One Time Required Payment | 25,000 | |||||||||||||||||||||
Litigation Settlement, Weekly Required Payment | $ 25,000 | |||||||||||||||||||||
Litigation Settlement, Payment | $ 3,006,015 | |||||||||||||||||||||
Discontinued Operations, Disposed of by Sale [Member] | Teco Sale [Member] | ||||||||||||||||||||||
Notes and Accrued Interest Payable, Exchange Reduction, Percentage (Rate) | Rate | 110.00% | 110.00% | ||||||||||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | $ 4,000,000 | $ 4,000,000 | ||||||||||||||||||||
Increase (Decrease) Liability Due from Exchange Reduction, Percentage (Rate) | Rate | 10.00% | 10.00% | ||||||||||||||||||||
Increase (Decrease) Liability Due from Exchange Reduction, Value | $ 125,686 | $ 125,686 | ||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||
Interest Expense, Debt, Total | 47,918 | |||||||||||||||||||||
Amortization of Debt Discount (Premium) | 276,191 | |||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 1,060,000 | 1,060,000 | ||||||||||||||||||||
Conversion of Convertible Notes Into Common Stock [Member] | ||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 7,944,000 | |||||||||||||||||||||
Warrants Issued in March 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.60 | $ 0.60 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | 3 years | ||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 8,000,000 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | |||||||||||||||||||||
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | |||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | shares | 788,000 | |||||||||||||||||||||
Warrants Related to July 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.65 | $ 0.60 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | |||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 28,804,000 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | |||||||||||||||||||||
Warrants Issued in September 30, 2023, Convertible Note Offering [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.10 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | |||||||||||||||||||||
Warrants and Rights Outstanding | $ 13,396 | |||||||||||||||||||||
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member] | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 46,886 | |||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 33,490 | |||||||||||||||||||||
Interest Expense, Debt, Total | 19,470 | |||||||||||||||||||||
Amortization of Debt Discount (Premium) | 10,564 | |||||||||||||||||||||
Interest Payable | 53,238 | 53,238 | ||||||||||||||||||||
Interest Payable, Accrued Prior to Extinguishments | $ 38,438 | |||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.05 | |||||||||||||||||||||
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 625,000 | 625,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 375,000 | 375,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | ||||||||||||||||||||||
Interest Expense, Debt, Total | 244,471 | |||||||||||||||||||||
Amortization of Debt Discount (Premium) | 216,974 | |||||||||||||||||||||
Convertible Notes Payable, Current | 258,296 | 258,296 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 116,704 | 116,704 | ||||||||||||||||||||
Convertible Notes Payable, Noncurrent | 166,645 | 166,645 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 83,355 | 83,355 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | 250,000 | ||||||||||||||||||||
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | 250,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Noncurrent | 83,355 | 83,355 | ||||||||||||||||||||
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 425,000 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 6,500 | 6,500 | 81,250 | |||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 347,000 | |||||||||||||||||||||
Proceeds from Convertible Debt | 50,000 | $ 543,750 | ||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 0 | $ 196,886 | ||||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | |||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 1,933,693 | |||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 904,690 | |||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 1,029,003 | |||||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 8,000,000 | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | |||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 7,201,000 | |||||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | 3 years | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 7,092,796 | |||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 3,142,605 | |||||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 3,950,191 | |||||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 28,804,000 | ||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | |||||||||||||||||||||
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.10 | |||||||||||||||||||||
Convertible Notes Payable, Total | 1,257,000 | 1,257,000 | $ 1,257,000 | |||||||||||||||||||
Debt Instrument, Extended Amount | $ 197,000 | |||||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.0375 | $ 0.06 | $ 0.17 | |||||||||||||||||||
Debt Instrument, Face Amount | $ 2,765,000 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 265,000 | |||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | $ 75,000 | $ 125,000 | |||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 440,000 | |||||||||||||||||||||
Payments for Brokerage Fees | $ 175,000 | |||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 1,333,333 | 1,250,000 | ||||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 64,706 | |||||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 10.00% | |||||||||||||||||||||
Debt Instrument, Debt Default, Interest Expense | $ 9,559 | |||||||||||||||||||||
Debt Instrument, Debt Default, Principal Expense | $ 276,500 | |||||||||||||||||||||
Debt Instrument, Debt Default, Increase in Principal Amount, Percent | 10.00% | |||||||||||||||||||||
Debt Default Penalty | $ 286,059 | |||||||||||||||||||||
Promissory Note [Member] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 1,625,272 | 1,625,272 | ||||||||||||||||||||
Short-term Debt, Total | 1,508,568 | 1,508,568 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 116,704 | 116,704 | ||||||||||||||||||||
Promissory Note [Member] | July 2017 Convertible Note Offering [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | |||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | |||||||||||||||||||||
Interest Payable | 144,994 | 144,994 | ||||||||||||||||||||
Short-term Debt, Total | $ 1,111,863 | $ 1,111,863 | ||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member] | ||||||||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 100.00% | |||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | ||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 8,823,529 | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.17 |
Note 6 - Capital Transactions (
Note 6 - Capital Transactions (Details Textual) - USD ($) | 9 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Jul. 18, 2021 | Mar. 31, 2020 | |
Proceeds from Warrant Exercises | $ 62,660 | $ 249,807 | ||
Share-based Payment Arrangement, Option [Member] | ||||
Share-based Payment Arrangement, Expense | 54,167 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 28,833 | |||
Share-based Payment Arrangement, Nonemployee [Member] | ||||
Share-based Payment Arrangement, Expense | $ 28,800 | |||
Warrants Issued to Investors in Private Placements [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.10 | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||
Warrants and Rights Outstanding, Term (Year) | 3 years | |||
Class of Warrant or Right, Exercises in Period (in shares) | 2,095,333 | |||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.03 | |||
Proceeds from Warrant Exercises | $ 56,394 | |||
Brokerage Fees for Issuance of Common Stock and Warrants | 6,266 | |||
Induced Dividend from Warrant Exercises | 163,017 | |||
Class of Warrant or Right, Exercised During Period, Intrinsic Value | 62,660 | |||
Class of Warrant or Right, Issued During Period, Fair Value | $ 100,357 | |||
Exercise of Warrants for Stock, Shares (in shares) | 2,088,667 | |||
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.03 | |||
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.05 | |||
Warrants Issued to Researcher as Compensation [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||
Class of Warrant or Right, Issued During Period (in shares) | 600,000 | |||
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share) | $ 0.05 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share) | $ 0.048 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | Dec. 16, 2020 | Sep. 17, 2020 | Jul. 14, 2020 | Apr. 22, 2020 |
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | ||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | |||
Litigation Settlement, Payment | $ 3,006,015 | |||
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member] | ||||
Loss Contingency, Damages Sought, Value | $ 73,050 | |||
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member] | ||||
Payments for Legal Settlements | $ 25,000 | |||
Reduction in Cost Basis of Fixed Asset Related to Litigation | $ 48,050 |
Note 8 - Related Party Transa_2
Note 8 - Related Party Transactions (Details Textual) | Dec. 31, 2021USD ($) |
Officers and Directors [Member] | |
Due to Related Parties, Total | $ 84,913 |
Note 9 - Sale of Membership I_3
Note 9 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) | Dec. 31, 2021USD ($) | Dec. 14, 2021USD ($) | Aug. 10, 2020USD ($) | Mar. 24, 2020USD ($) | Nov. 27, 2019 | Oct. 23, 2017 | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Mar. 31, 2021USD ($) |
Notes Reduction | $ 2,612,854 | $ 0 | ||||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | 0 | ||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 3,025,000 | $ 3,025,000 | $ 3,025,000 | 3,025,000 | $ 0 | |||||||
Deconsolidation, Gain (Loss), Amount | $ 5,206,208 | 5,206,208 | $ 0 | 5,206,208 | $ 0 | |||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | ||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | |||||||||||
GB Sciences Nopah, LLC [Member] | ||||||||||||
Sale of Stock, Percentage of Ownership | 100.00% | |||||||||||
Noncash or Part Noncash Divestiture, Amount of Consideration Received | $ 312,315 | |||||||||||
Nevada Subsidiaries [Member] | ||||||||||||
Sale of Stock, Percentage of Ownership | 100.00% | |||||||||||
Teco Subsidiaries [Member] | ||||||||||||
Sale of Stock, Consideration Received on Transaction | $ 8,000,000 | |||||||||||
Notes Receivable, Interest Rate | 8.00% | |||||||||||
GB Sciences Nopah, LLC [Member] | ||||||||||||
Notes Reduction | $ 237,668 | |||||||||||
Extinguishment of Debt, Amount | 3,588,540 | |||||||||||
Sale of Stock, Percentage of Ownership before Transaction | 100.00% | |||||||||||
Sale of Stock, Percentage of Ownership after Transaction | 0.00% | |||||||||||
Proceeds from Divestiture of Interest in Consolidated Subsidiaries | 1,648,772 | |||||||||||
Proceeds From Divestiture of Business, Advances Received | $ 400,000 | 400,000 | 400,000 | 400,000 | ||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 3,025,000 | $ 3,025,000 | $ 3,025,000 | $ 3,025,000 | ||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 8.00% | |||||||||||
Note Receivable, Interest Only, Monthly | $ 60,500 | |||||||||||
Quarterly Interest Only Payments on Note Receivable, Years | 1 | 1 | 1 | 1 | ||||||||
Number of Quarterly Principal and Interest Payments on Note Receivable | 7 | 7 | 7 | 7 | ||||||||
Note Receivable, Quarterly Principal and Interest Installment | $ 201,774 | |||||||||||
Final Payment, Principal and Interest Payments Due on Note Receivable | $ 2,014,225 | $ 2,014,225 | $ 2,014,225 | 2,014,225 | ||||||||
Deconsolidation, Gain (Loss), Amount | $ 5,206,208 | |||||||||||
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member] | ||||||||||||
Extinguishment of Debt, Amount | $ 74,647 | $ 74,647 |
Note 9 - Sale of Membership I_4
Note 9 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Proceeds from sale of Nevada subsidiaries | $ 1,648,772 | $ 0 | |||
Note receivable from sale of Nevada subsidiaries | 3,025,000 | 0 | |||
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates | 2,612,854 | 0 | |||
Extinguishment of accrued management fees due to purchaser | 850,000 | 0 | |||
GAIN ON DECONSOLIDATION | $ 5,206,208 | $ 5,206,208 | $ 0 | $ 5,206,208 | $ 0 |
Nevada Subsidiaries [Member] | |||||
Proceeds from sale of Nevada subsidiaries | 1,648,772 | ||||
Note receivable from sale of Nevada subsidiaries | 3,025,000 | ||||
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates | 2,612,854 | ||||
Extinguishment of accrued management fees due to purchaser | 850,000 | ||||
Total consideration | 8,136,626 | ||||
Carrying amount of assets | 7,130,159 | ||||
Carrying amount of liabilities | (4,199,741) | ||||
Net assets deconsolidated | $ 2,930,418 |
Note 9 - Sale of Membership I_5
Note 9 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) (Parentheticals) | Dec. 31, 2021USD ($) |
Nevada Subsidiaries [Member] | |
Advancements | $ 400,000 |
Note 10 - Subsequent Events (De
Note 10 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) | Jan. 20, 2022 | Jan. 14, 2022 |
Payments for Deferred Compensation | $ 84,913 | |
Convertible Debt [Member] | ||
Repayments of Convertible Debt | $ 500,000 | |
Convertible Notes Payable, Total | $ 1,060,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.00% |